Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969706 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Patients with Oligodendroglioma
A Phase 2 study of Oligodendroglioma, Adult, sponsored by Stephen Bagley, MD, MSCE.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03969706 is a Phase 2 study of Oligodendroglioma, Adult that is active but no longer recruiting, run by Stephen Bagley, MD, MSCE. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03969706, a Phase 2 study of Oligodendroglioma, Adult, is active but no longer recruiting, sponsored by Stephen Bagley, MD, MSCE.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma
Conditions Studied
Interventions
- DRUG Abemaciclib 200 MG
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2027-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03969706
The ClinicalTrials.gov registry entry for NCT03969706 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephen Bagley, MD, MSCE, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oligodendroglioma, Adult appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib 200 MG is the first listed.
NCT03969706 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03969706 about?
NCT03969706 is a clinical study titled "Abemaciclib in Patients with Oligodendroglioma". This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma
What is the current status of trial NCT03969706?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-05-15. Estimated completion is 2027-05-15.
What conditions does trial NCT03969706 study?
This clinical trial studies the following conditions: Oligodendroglioma, Adult.
What interventions are being tested in trial NCT03969706?
The interventions under investigation include: Abemaciclib 200 MG (DRUG).
Who is sponsoring clinical trial NCT03969706?
This trial is sponsored by Stephen Bagley, MD, MSCE, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03969706 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oligodendroglioma, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.